Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
David R SpigelCorinne Faivre-FinnJhanelle E GrayDavid VicenteDavid PlanchardLuis G Paz-AresJohan Filip VansteenkisteMarina-Chiara GarassinoRina HuiXavier QuantinAndreas RimnerYi-Long WuMustafa ÖzgüroğluKi Hyeong LeeTerufumi KatoMaike de WitTakayasu KurataMartin ReckByoung Chul ChoSuresh SenanJarushka NaidooHelen MannMichael NewtonPiruntha ThiyagarajahScott J AntoniaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
These updated analyses demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy. An estimated 42.9% of patients randomly assigned to durvalumab remain alive at 5 years and 33.1% of patients randomly assigned to durvalumab remain alive and free of disease progression, establishing a new benchmark for standard of care in this setting.